Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 |
Tel: | 1-617-2832856 |
Website: | https://www.annovisbio.com |
IR: | See website |
Key People | ||
Maria L. Maccecchini President, Chief Executive Officer, Founder, Director | Henry Hagopian Chief Financial Officer |
Business Overview |
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer's disease (AD), Parkinson's disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three. |
Financial Overview |
For the fiscal year ended 31 December 2023, Annovis Bio Inc revenues was not reported. Net loss increased from $25.3M to $56.2M. Higher net loss reflects Research and development - Balancin increase from $13.1M to $36.6M (expense), General and administrative increase of 19% to $3.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$3.10 to -$6.23. |
Employees: | 6 as of Feb 29, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $125.06M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$45.04M as of Dec 31, 2023 |
Net annual income (TTM): | -$56.20M as of Dec 31, 2023 |
Free cash flow (TTM): | -$39.97M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 11,011,299 as of Mar 26, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |